Compounds, compositions and methods
US-2021292311-A1 · Sep 23, 2021 · US
Modulators of eukaryotic initiation factor 2B, compositions and methods
US11236100B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11236100-B2 |
| Application number | US-201816637718-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 8, 2018 |
| Priority date | Aug 9, 2017 |
| Publication date | Feb 1, 2022 |
| Grant date | Feb 1, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, selected from the group consisting of: 2. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, and a pharmaceutically acceptable carrier. 3. A compound having the structure: or a pharmaceutically acceptable salt thereof. 4. A pharmaceutical composition comprising a compound of claim 3 , or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. 5. A compound having the structure: or a pharmaceutically acceptable salt thereof. 6. A pharmaceutical composition comprising a compound of claim 5 , or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. 7. A compound having the structure: or a pharmaceutically acceptable salt thereof. 8. A pharmaceutical composition comprising a compound of claim 7 , or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. 9. A compound having the structure: or a pharmaceutically acceptable salt thereof. 10. A pharmaceutical composition comprising a compound of claim 9 , or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. 11. A compound having the structure: or a pharmaceutically acceptable salt thereof. 12. A pharmaceutical composition comprising a compound of claim 11 , or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. 13. A compound having the structure: or a pharmaceutically acceptable salt thereof. 14. A pharmaceutical composition comprising a compound of claim 13 , or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. 15. A compound having the structure: or a pharmaceutically acceptable salt thereof. 16. A pharmaceutical composition comprising a compound of claim 15 , or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. 17. A compound having the structure: or a pharmaceutically acceptable salt thereof. 18. A pharmaceutical composition comprising a compound of claim 17 , or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. 19. A compound having the structure: or a pharmaceutically acceptable salt thereof. 20. A pharmaceutical composition comprising a compound of claim 19 , or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. 21. A compound having the structure: or a pharmaceutically acceptable salt thereof. 22. A pharmaceutical composition comprising a compound of claim 21 , or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. 23. A compound having the structure: or a pharmaceutically acceptable salt thereof. 24. A pharmaceutical composition comprising a compound of claim 23 , or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. 25. A compound having the structure: or a pharmaceutically acceptable salt thereof. 26. A pharmaceutical composition comprising a compound of claim 25 , or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. 27. A compound having the structure: or a pharmaceutically acceptable salt thereof. 28. A pharmaceutical composition comprising a compound of claim 27 , or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. 29. A compound having the structure: or a pharmaceutically acceptable salt thereof. 30. A pharmaceutical composition comprising a compound of claim 29 , or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
Assignees
Inventors
Classifications
1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles · CPC title
linked by a carbon chain containing aromatic rings · CPC title
attached in position 2 · CPC title
2-Pyrrolones · CPC title
with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11236100B2 cover?
- The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.
- Who is the assignee on this patent?
- Denali Therapeutics Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D413/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 10 related publications on this page (citations in our corpus or others sharing the same primary CPC).